COMMUNIQUÉ DE PRESSE
News
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
q.beyond gains Thorsten Dirks as new Supervisory Board member
Thorsten Dirks appointed as new member of q.beyond AG's Supervisory Board following approval from the Cologne District Court. The former CEO of Telefónica Deutschland and past President of Bitkom will succeed Dr. Frank Zurlino, bringing valuable expertise in digitalization -
COMMUNIQUÉ DE PRESSE
APONTIS PHARMA successfully completes performance and efficiency improvement program
APONTIS PHARMA successfully completes performance and efficiency improvement program, reducing headcount and expenses. New go-to-market approach for Single Pill combinations to start on 1 March 2024 -
COMMUNIQUÉ DE PRESSE
Infineon with robust Q1 FY 2024. Market environment outside automotive remains weak. Weaker currency and markets are leading to an adjustment of FY 2024 outlook
Infineon reports robust Q1 FY 2024 results with €3.702 billion revenue and a 22.4% segment result margin. FY 2024 outlook adjusted due to weaker currency and markets -
COMMUNIQUÉ DE PRESSE
hGears AG Group: Preliminary 2023 free cash flow significantly better than Management’s guidance; adjusted EBITDA in line despite marginal revenues miss
hGears AG Group reports preliminary 2023 financial results, with higher free cash flow surpassing management's guidance and adjusted EBITDA meeting expectations despite marginal revenue miss. Countermeasures were implemented to preserve profitability -
COMMUNIQUÉ DE PRESSE
Sensirion expands its production site in Debrecen with support from a build-to-suit partner
Sensirion expands its production site in Debrecen, Hungary by 5,000 m² with support from a build-to-suit partner. The expansion will significantly increase production capacity for sensor modules and aligns with Sensirion's sustainable growth strategy and job creation in Hungary -
COMMUNIQUÉ DE PRESSE
Courts of Basel-Stadt have revoked bankruptcy of Kinarus Therapeutics Holding AG
Courts of Basel-Stadt have revoked the bankruptcy of Kinarus Therapeutics Holding AG, a SIX Swiss Exchange listed therapeutic drug development company. The revocation is a condition for the business combination with Curatis AG
